Qiagen N.V.
QGEN
Pozycja w akcjach
#2153
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Cena akcji
$46.17
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$9.51B
Zmiana (1 dzień)
0.02%
Zmiana (1 rok)
-4.35%
Kraj
NL
Handel Qiagen N.V. (QGEN)
Kategoria
Healthcare
Marża operacyjna dla Qiagen N.V. (QGEN)
Marża operacyjna na dzień October 2026 TTM: 25.33%
Według najnowszych raportów finansowych i ceny akcji Qiagen N.V., bieżąca marża operacyjna (TTM) wynosi 25.33%. Na koniec 2024 wynosiła 4.94%.
Historia marży operacyjnej dla Qiagen N.V. od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 25.33% | 1.73% |
| 2025 | 24.90% | 404.05% |
| 2024 | 4.94% | -76.32% |
| 2023 | 20.86% | -15.95% |
| 2022 | 24.82% | -11.29% |
| 2021 | 27.98% | 35.43% |
| 2020 | 20.66% | -1,308.19% |
| 2019 | -1.71% | -109.63% |
| 2018 | 17.75% | 64.05% |
| 2017 | 10.82% | 46.41% |
| 2016 | 7.39% | -47.25% |
| 2015 | 14.01% | 16.56% |
| 2014 | 12.02% | 147.33% |
| 2013 | 4.86% | -64.11% |
| 2012 | 13.54% | 59.11% |
| 2011 | 8.51% | -50.92% |
| 2010 | 17.34% | -2.86% |
| 2009 | 17.85% | 9.44% |
| 2008 | 16.31% | 27.52% |
| 2007 | 12.79% | -40.79% |
| 2006 | 21.60% | -9.24% |
| 2005 | 23.80% | 7.64% |
| 2004 | 22.11% | 12.81% |
| 2003 | 19.60% | 35.55% |
| 2002 | 14.46% | -28.66% |
| 2001 | 20.27% | 13.18% |
| 2000 | 17.91% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 17.97% | -99.29% |
US
|
|
| 20.42% | -99.19% |
US
|
|
| -10.70% | -100.42% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -99.12% |
US
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.